An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | ||
| Net Income | -2,048 | -13,603 |
| Accounts payable and accrued liabilities | 379 | N/A |
| Other Working Capital | 497 | 1,224 |
| Other Operating Activity | -371 | 7,015 |
| Operating Cash Flow | $-1,543 | $-5,364 |
| Cash Flows From Investing Activities | ||
| Investing Cash Flow | $N/A | $0 |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | 10 | N/A |
| Other Financing Activity | 79,734 | 3,836 |
| Financing Cash Flow | $79,744 | $3,836 |
| Beginning Cash Position | 4,070 | 5,598 |
| End Cash Position | 82,271 | 4,070 |
| Net Cash Flow | $78,201 | $-1,528 |
| Free Cash Flow | ||
| Operating Cash Flow | -1,543 | -5,364 |
| Free Cash Flow | -1,543 | -5,364 |